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Background: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease mediated by T cells. The aim of the
present study was to investigate the therapeutic efficacy of synthetic peptides (HP-R1, HP-R2 and HP-R3), derived from
the sequence of 65-kD mycobacterial heat shock protein (HSP), in the treatment of RA using adjuvant-induced arthritis
(AA) animal model.
Methods: AA was induced by a single intradermal injection Freund’s complete adjuvant in male Lewis rats. At the first
clinical sign of disease, rats were administered nasally by micropipette of peptides or phosphate buffer saline (PBS).
Disease progression was monitored by measurement of body weight, arthritis score and paw swelling. The changes of
histopathology were assessed by hematoxylin eosin staining. The serum levels of tumor necrosis factor (TNF) - alpha
and interleukin (IL)-4 were measured by enzyme-linked immunosorbent assay (ELISA).
Results: The peptides efficiently inhibited the footpad swelling and arthritic symptoms in AA rats. The synthetic
peptides displayed significantly less inflammatory cellular infiltration and synovium hyperplasia than model controls.
This effect was associated with a suppression of pro-inflammatory cytokine TNF-alpha production and an increase of
anti-inflammatory cytokine IL-4 production after peptides treatment.
Conclusions: These results suggest that the synthetic peptides derived from HSP65 induce highly effective protection
against AA, which is mediated in part by down-regulation of inflammatory cytokines, and support the view that the
synthetic peptides is a potential therapy for RA that may help to diminish both joint inflammation and destruction.
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Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease, characterized by the presence of inflammatory syno-
vitis and destruction of joint cartilage and bone. This
disease leads to severe pain and reduces life expectancy.
The underlying immunologic mechanisms and etiologic
factors responsible for the initiation and development of
RA are not yet fully understood, but it is well established
that inflammation and bone destruction plays crucial roles
in RA. RA is specifically characterized by enhanced pro-
duction of tumor necrosis factor (TNF)-alpha, interferon-
gamma (IFN) - gamma, interleukin (IL)-6 and IL-17, and* Correspondence: jzhou829@126.com
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unless otherwise stated.in the affected joints [1-3]. Therefore, therapeutic agents
which possess anti-inflammatory and immunosuppressant
activity will provide important benefits and promises in
the treatment of RA. Non-steroidal anti-inflammatory
drugs (NSAIDs) such as indomethacin and celecoxib, rep-
resent an effective therapy for treating RA. Disappoint-
ingly, this kind of medicine has side-effects including
gastric ulcer and the cardiovascular risk, which has limited
its use [4-6]. Therefore, there is still an unmet need for
improved therapies for RA.
Heat shock proteins (HSPs) are ubiquitous housekeep-
ing proteins found in virtually all living organisms. HSPs
have been a subject of expanding interest in human and
experimentally induced autoimmune diseases, both as po-
tential antigens and as intracellular chaperones involved
in peptide binding to human leucocyte antigens. Previous. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mycobacterial HSP60 peptide induces highly effective
protection against adjuvant-induced arthritis (AA), an
experimental arthritis model with close histopathologic
resemblance to RA [7,8]. Notably, our recent study has
demonstrated that the synthetic peptides from HSP65
inhibit pro-inflammatory cytokine secretion by periph-
eral blood mononuclear cells from RA patients [9].
However, there is no scientific evidence to prove the
effectiveness of the synthetic peptides from HSP65 on
RA in the vivo model. In the present study, we employed
AA rat model and treated the rats with Heat shock
protein- derived peptide (HP). To investigate the thera-
peutic effect of these peptides, we detected arthritis se-




Male inbred Lewis rats (6–9 weeks old) were obtained
from the Vital River Laboratory Animal Technology Co.
Ltd. (Beijing, China). Rats were maintained under
climate-controlled conditions under 12-h dark–light
cycle and had unlimited access to water and standard rat
chow. All experimental procedures were performed in
accordance with the Guidelines for the Care and Use of
Laboratory Animals issued by the Chinese Council on
Animal Research and the Guidelines of Animal Care.
This study was approved by the ethics committee of
Xi’an Jiaotong University.
Materials
Freund’s complete adjuvant (FCA) was obtained from
sigma (St. Louis, MO, USA). Three peptides used in this
study were identified by bioinformatics tools and comprised
dominant epitopes recognized by T cells. The peptides are
protected by a patent (CN 200810150035.8). Three 15-mer
peptides (HP-R1, QKRAAQDAAVDAACG; HP-R2, QKR
AAQAARVEAACG; and HP-R3, QKLFKTLQSLFADFN)
were synthesized by Chengdu Kaijie Biomedical Technol-
ogy Development (Chengdu, China). The purity of the HP-
R1, HP-R2 and HP-R3 peptides was 99.13%, 96.84% and
98.14%, respectively. All three peptides had good antigenic-
ity and immunogenicity.
Adjuvant induced arthritis and peptide immunotherapy
protocols
Rats were lightly anesthetized with ether and adjuvant
arthritis (AA) was induced by a single intradermal (i.d.)
injection in the base of the tail with 150 μl FCA com-
posed of heat-killed and dried Mycobacterium tubercu-
losis (strain H37Ra, ATCC 25177) suspended in paraffin
oil and mannide monooleate. Rats were inspected daily
for the onset of arthritis as characterized by edema anderythema in the paws. Peptide was administered on day
10, 13, 16, and 19 after induction of arthritis with FCA.
Briefly, 100 μg of peptide dissolved in phosphate buffer
saline (PBS) (peptide concentration 10 mg/ml) was ad-
ministered nasally in a total volume of 10 μl (5 μl per
nostril) using a micropipette. An equal volume of PBS
was given rats in control group and AA model group.
Every group consists of 9 animals [10].
Assessment of arthritis
Arthritis disease progression and severity were evaluated
by arthritic clinical scoring, measurement of hind paw
volumes and body weight for every two days following
induction of arthritis in a blinded manner. Hind paw
volumes were observed by rat paw volume measurement
instrument. The level of arthritic inflammation of each
paw was graded from 0 to 4 based on degree of swelling,
erythema and deformation of the joints: 0 = normal; 1 =
slight erythema or swelling of one of the toe or fingers;
2 = erythema and swelling of two toes or fingers; 3 = se-
vere erythema and swelling of the ankle or wrist; 4 =
complete erythema and swelling of toes or fingers, joint
deformity and lack of flexibility. Thus the maximum
score was 16 [11].
Biochemical studies
On day 28 after the induction of arthritis the rats were
sacrificed by CO2 inhalation, after which blood samples
and hind limb joints were collected. Blood samples were
centrifuged at 1500 g for 10 min at 4°C and serum was
aliquoted and stored at −80°C until assay. Cytokines
were measured by using enzyme-linked immunosorbent
assay (ELISA). Briefly, the concentrations of inflamma-
tory cytokine TNF-alpha and IL-4 in serum were quanti-
fied by using commercial cytokine ELISA kit (R&D
systems, Minneapolis, USA) and performed in duplicate
according to the manufacturer’s instructions.
Histopathological studies
Hind limb joints were collected on day 28 after the in-
duction of arthritis, after the rats were sacrificed by CO2
inhalation. The ankle joints were fixed in 10% buffered
formalin for 24 h and decalcified in 10% ethylene di-
amine tetraacetate (EDTA) solution. After decalcifica-
tion, tissues were dehydrated, processed, and embedded
in paraffin wax. 5 μm serial sections from each block
were prepared, stained with haematoxylin and eosin
(H&E) and observed under a light microscopy.
Statistical analysis
Data are presented as the mean ± SEM. Statistical analysis
was performed by one-way analysis of variance followed
by Tukey post-hoc test for multiple comparisons. The sig-
nificant level was set at a two-tailed P < 0.05. All figures
Figure 2 Effect of HP-R1, HP-R2 and HP-R3 on arthritic score of
AA rats. Adjuvant Arthritis was induced on day 0 with Freund’s
Complete Adjuvant (FCA). 100 μg peptides were administered
nasally by micropipette on day 10, 13, 16, and 19 after FCA injection.
An equal volume of PBS was given rats in control group and AA
model group. Arthritis score was assessed every other day from day
8 onward. Data are presented as mean ± SEM, n =9 rats per group.
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Results
Effects of peptides on body weight of AA rats
Body weight of the rats in control group growed steadily.
The body weight of AA rats after FCA injection declined
sharply, followed by slow growth. Peptides HP-R2 and
HP-R3 significantly inhibited the decrease (P < 0.05) in
body weight of AA rats on day 12 following FCA injec-
tion, compared to AA model group. The AA rats exhib-
ited significant body weight gain (P < 0.05) in HP-R3
group; while the HP-R1 and HP-R2 also increased the
body weight of AA rats, there was no significant differ-
ence (Figure 1).
Effect of peptides on arthritic score of AA rats
The arthritic index represents the grade of arthritis that
was used to assess efficacy of three peptides. In the AA
group, diseased rats without any treatment showed an
increased arthritic index starting on day 10 to a peak on
day 28. Compared with AA group, administration of
HP-R1 significantly (P < 0.05) reduced arthritis score on
day 22, 26, 28 and 34. HP-R2 and HP-R3 were observed
to have significantly strong activity in preventing pro-
gression of arthritic disease, and arthritis score of AA
rats were found to be significantly lowered (P < 0.05)
from day 20 to day 34 (Figure 2).
Effect of peptides on paw swelling of AA rats
The paw swelling in AA rat model also represents the
severity of arthritis. We showed the paw swelling of ratsFigure 1 Effect of HP-R1, HP-R2 and HP-R3 on body weight of
AA rats. Adjuvant Arthritis was induced on day 0 with Freund’s
Complete Adjuvant (FCA). 100 μg peptides were administered
nasally by micropipette on day 10, 13, 16, and 19 after FCA injection.
An equal volume of PBS was given rats in control group and AA
model group. Starting on day 8, the rats were weighed every two
days. Data are presented as mean ± SEM, n =9 rats per group.
*P < 0.05 when compared to control group, #P < 0.05 when
compared to AA group.when arthritis score was reached to a maximum on day
28. Compared with control group, paw swelling of the
rats increased significantly in AA model group (P <
0.05). Although HP-R1 and HP-R2 tended to inhibit
footpad swelling, the difference did not reach statistical
significance. HP-R3 owed significant inhibitory activity
in paw swelling compared to AA model group (P < 0.01).
(Figure 3).
Effect of peptides on biochemical parameters
Effect of three peptide on biochemical parameters was
examined in AA rats by measuring serum cytokine
(TNF-alpha and IL-4) levels on day 34 after adjuvant in-
jection. Compared to the lower serum cytokine levels
found in control rats, serum TNF-alpha levels were sig-
nificantly increased (P < 0.01) in AA rats (Figure 4A).
Treatment of AA rats with three peptides resulted in a
significant decrease in serum TNF-alpha level as com-
pared to the high serum TNF-alpha levels found in AA
rats. Notably, anti-inflammatory cytokine IL-4 levels
were significantly (P < 0.05) increased in HP-R2 and
HP-R3 treated group (Figure 4B).
Effect of peptides on histopathology of arthritic paws
Histological analysis revealed that no synovial hyperplasia,
inflammatory cell infiltration or tissue destruction were
seen in control group by H&E staining (Figure 5A). In
contrast, the ankle joint of AA rats in model group
showed prominent synovial hyperplasia, inflammatory cel-
lular infiltration and severe pannus formation (Figure 5B).
Compared with AA model group, cellular infiltration and
synovium hyperplasia were markedly reduced in the rats
treated with three peptides (Figure 5C-E).
Figure 3 Effect of HP-R1, HP-R2 and HP-R3 on paw swelling of
AA rats. Adjuvant Arthritis was induced on day 0 with Freund’s
Complete Adjuvant (FCA). 100 μg peptides were administered
nasally by micropipette on day 10, 13, 16, and 19 after FCA injection.
An equal volume of PBS was given rats in control group and AA
model group. Paw swelling was assessed when arthritis score
reached a maximum on day 28. Data are presented as mean ± SEM,
n =9 rats per group. *P < 0.05 when compared to control group,
##P < 0.01 when compared to AA group.
Figure 4 Effect of HP-R1, HP-R2 and HP-R3 on the levels of
TNF-alpha (A) and IL-4 (B) in serum. Serum of rats was collected
on day 28 after FCA injection and measured with ELISA kits. Data are
presented as mean ± SEM, n = 9 rats per group. **P < 0.01 when
compared to control group, #P < 0.05, ##P < 0.01 when compared to
AA group.
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age cells of AA rats. The results in control group
showed smooth articular cartilage surface and cartilage
cells arranged in neat rows (Figure 6A). In contrast, AA
model group revealed that there were rough cartilage
surface, small cracks, a small amount of clumping of the
cartilage cells, and significantly increased cartilage cells
(Figure 6B). However, cartilage cells were markedly re-
duced and smooth cartilage surface was also observed
in the rats treated with three peptides compared with
AA model group (Figure 6C-E).
Discussion
RA is characterized by synovial inflammation, destruc-
tion of cartilage and bone, severe joint pain, and ultim-
ately life-long crippling. In the present study, the
synthetic peptides derived from HSP65 were studied for
their efficacy on RA treatment employing an adjuvant-
induced arthritis rat model, which is extensively used for
studies regarding the pathogenesis of autoimmune arth-
ritis as well as for the validation of the efficacy of anti-
rheumatic drugs because it has various similarities to
human RA [12-14]. Administrations of three peptides
from the day of disease onset significantly inhibited the
arthritic clinical scoring and paw swelling. We also ob-
served dampening effects on TNF-alpha concomitant
with dramatic increases in IL-4 production in the serum
after peptides treatment, which was relevant to inhibit-
ing arthritic progression. These findings were positively
consistent with the results of histological examinations,
which reduced cellular infiltration and synovium hyper-
plasia in the peptide-treated groups.
The disease onset in rats commenced from day 10 and
reached maximum on day 28 in the adjuvant induced
(disease control) arthritic rats. The synthetic peptides
from HSP65 efficiently inhibited the progression of AA
with a significant reduction of the clinical score. The
most important index for evaluation of arthritis is the
footpad swelling, and these peptides showed the ability
to inhibit the paw swelling of AA rats. Inflammatory cel-
lular infiltration and prominent synovial hyperplasia
were observed in H&E tissue sections of arthritic control
animals. In contrast, the histopathological changes were
restored to normal stage after giving treatment with
three peptides.
Pro-inflammatory cytokines TNF-alpha, IL-1bata, and
IFN-gamma produced by macrophages and other immune
cells are of decisive importance in the pathogenesis and
progression of RA [1-3]. Among the T cell, the T-helper
(Th1) cells secrete TNF- alpha and IFN-gamma, whereas
the counter-regulatory Th2 cells secrete IL-4 and IL-10
[7]. The role of Th1-Th2 balance plays an important role
in regulation of autoimmunity [15,16]. In view of the crit-
ical role of pro-inflammatory cytokines in RA, scientists
Figure 5 Effects of HP-R1, HP-R2 and HP-R3 on histopathology of arthritic paws. A: Control group; B: AA model group; C: AA rats
administered with HP-R1; D: HP-R2; E: HP-R3. (H&E staining, magnification 10×). n = 4 per treatment group.
Shi et al. BMC Musculoskeletal Disorders 2014, 15:253 Page 5 of 7
http://www.biomedcentral.com/1471-2474/15/253intend to design drugs for suppression of this disease via
anti-inflammation. There is substantial evidence demon-
strating the importance of TNF-alpha in the inflammatory
process of RA [9,17], and this cytokine is better value to
assess the degree of the arthritis and also good targets for
treating the disease. Drugs that block pro-inflammatory
cytokines TNF-alpha can improve outcomes for RA [18].
However, the anticytokine biologics are costly in the treat-
ment of RA [19]. In the current study, the serum levels of
TNF-alpha in arthritic rats were dramatically up-regulated
as compared to control rats and these levels were mark-
edly reduced after treatment with the synthetic peptides.
Of note, HP-R2 and HP-R3 also increased levels of IL-4,
resulting in an overall anti-inflammatory effect. IL-4 has
been identified as a crucial anti-inflammatory cytokine inFigure 6 Effects of HP-R1, HP-R2 and HP-R3 on cartilage cells of AA r
HP-R1; D: HP-R2; E: HP-R3. (H&E staining, magnification 10×). n = 4 per treatRA [20-23]. It is important to detect other cytokines such
as IFN-gamma and IL-10. Our recent study has demon-
strated that the secretion of IFN-gamma by peripheral
blood mononuclear cells from RA patients was signifi-
cantly suppressed by these synthetic peptides [9]. The
peptides tended to increase IL-10, although the effect did
not reach statistical significance. It was suggested that
these peptides conferred the ability in treatment of RA via
the inhibition of inflammation response.
It has been shown that disease-protective peripheral T
cell tolerance can be induced through oral or nasal admin-
istration of an antigen [8]. Successful experiments in RA
rat models have shown promising results using HSP
peptides to modulate the arthritis disease [8,24,25]. Based
on previous studies [25,26] and our current results, theats. A: Control group; B: AA model group; C: AA rats administered with
ment group.
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regulatory T cells that may down-regulate the autoimmune
responses by the release of suppressor cytokines, and as a
result, the inflammation is suppressed. Compared with or-
ally induced tolerance, nasally induced tolerance has been
shown to be equally or, in the case of a peptide antigen,
even more effective in curbing experimental autoimmune
diseases [8,27]. Similar to oral tolerance, three distinct
mechanisms (e.g., clonal deletion, clonal anergy, and active
suppression) are possibly operational in nasal induced toler-
ance [24,27].
Recent study has demonstrated that an altered peptide
ligand derived from HSP60 induces the activation of T
cells by modifying cell cycle phase’s distribution of CD4+
T cells from RA patients [26]. Thus, CD4+ T cells may be
involved in the immunomodulatory effects elicited by the
three HSP peptides in the present study. Further investiga-
tions are clearly required to detect the immunophenotype
of the immune cells and elucidate which cells are HSP65
targets.
In conclusion, the results of the present study suggest
that synthetic peptides containing a T cell-dominant epi-
tope could efficiently inhibit the progression of AA with a
significant reduction of the clinical and histopathogic
score. This effect was associated with a suppression of
TNF-alpha production and an increase of IL-4 production,
which may indicate the presence of a Th2 type tolerogenic
mechanism. The present study has led to the identification
of a promising peptide candidate for RA treatment. Be-
sides the possibility to use them as a therapeutic drug,
they can be used as tools to define the antigen (epitope).Conclusion
These results suggest that the synthetic peptides derived
from HSP65 induce highly effective protection against AA,
which is mediated in part by down-regulation of inflamma-
tory cytokines, and support the view that the synthetic pep-
tides is a potential therapy for RA that may help to
diminish both joint inflammation and destruction.
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